Goldman Sachs Added Teva Pharmaceutical (TEVA) to its Conviction Buy List
More News related to TEVA
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Teva Receives Final Approval for Generic Prevacid(R) Delayed-Release Capsules
- Teva Pharma (TEVA) Announces Generic Version of Prevacid Does Not Infringe on Patents
- Teva Receives Favorable Court Decision Regarding Generic Prevacid(R) SoluTab
- Teva Pharma (TEVA) Seeks to Amend Existing Complaint Against Momenta Pharma over Copaxone Patent Infringement
More News related to Analyst Comments
- Soleil Securities Maintains a 'Buy' on TRW Automotive (TRW); Raises PT & Estimates
- Soleil Securities Maintains a 'Buy' on Toll Brothers (TOL); Adjusts Estimates
- Callaway (ELY) Indicated Higher as Wedbush Adds to 'Best Ideas List'
- FBR Capital Maintains an 'Outperform' on Tyco (TYC); Raises PT & Estimates
- FBR Capital Reiterates an 'Outperform' on KKR Financial (KFN); Warrants Premium Valuation
Goldman Sachs added Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) to its Conviction Buy List.
Teva Pharmaceutical Industries Limited develops, manufactures, and markets generic and human pharmaceuticals, as well as active pharmaceutical ingredients.
Shares of TEVA fell 8.5% yesterday following disappointing data on 40mg dosage strength of Copaxone.
Related Categories
Analyst CommentsStocks Mentioned
+0.22Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
